Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 2000 Jun 13;162(12):S3–S23.

An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori

S J Veldhuyzen van Zanten 1, N Flook 1, N Chiba 1, D Armstrong 1, A Barkun 1, M Bradette 1, A Thomson 1, F Bursey 1, P Blackshaw 1, D Frail 1, P Sinclair 1
PMCID: PMC1232536  PMID: 10870511

Abstract

OBJECTIVES: To provide Canadian primary care physicians with an evidence-based clinical management tool, including diagnostic and treatment recommendations, for patients who present with uninvestigated dyspepsia. RECOMMENDATIONS: The management tool has 5 key decision steps addressing the following: (1) evidence that symptoms originate in the upper gastrointestinal tract, (2) presence of alarm features, (3) use of nonsteroidal anti-inflammatory drugs (NSAIDs), (4) dominant reflux symptoms and (5) evidence of Helicobacter pylori infection. All patients over 50 years of age who present with new-onset dyspepsia and patients who present with alarm features should receive prompt investigation, preferably by endoscopy. The management options for patients with uninvestigated dyspepsia who use NSAIDs regularly are: (1) to stop NSAID therapy and assess symptomatic response, (2) to treat with NSAID prophylaxis if NSAID therapy cannot be stopped or (3) to refer for investigation. Gastroesophageal reflux disease can be diagnosed clinically if the patient's dominant symptoms are heartburn or acid regurgitation, or both; these patients should be treated with acid suppressive therapy. The remaining patients should be tested for H. pylori infection, and those with a positive result should be treated with H. pylori-eradication therapy. Those with a negative result should have their symptoms treated with optimal antisecretory therapy or a prokinetic agent. VALIDATION AND EVIDENCE: Evidence for resolution of the dyspepsia symptoms was the main outcome measure. Supporting evidence for the 5 steps in the management tool and the recommendations for treatment were graded according to the strength of the evidence and were endorsed by consensus of committee members. If no randomized controlled clinical trials were available, the recommendations were based on the best available evidence. LITERATURE REVIEW: Evidence was obtained from MEDLINE searches for pertinent articles published from 1966 to October 1999. The searches focused on dyspepsia, diagnosis and treatment. Additional articles were retrieved through a manual search of bibliographies and abstracts from international gastroenterology conferences.

Full Text

The Full Text of this article is available as a PDF (556.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adang R. P., Vismans J. F., Talmon J. L., Hasman A., Ambergen A. W., Stockbrügger R. W. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. Gastrointest Endosc. 1995 Nov;42(5):390–397. doi: 10.1016/s0016-5107(95)70037-4. [DOI] [PubMed] [Google Scholar]
  2. Agréus L., Svärdsudd K., Nyrén O., Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995 Sep;109(3):671–680. doi: 10.1016/0016-5085(95)90373-9. [DOI] [PubMed] [Google Scholar]
  3. Agréus L., Talley N. J. Dyspepsia: current understanding and management. Annu Rev Med. 1998;49:475–493. doi: 10.1146/annurev.med.49.1.475. [DOI] [PubMed] [Google Scholar]
  4. Agréus L., Talley N. Challenges in managing dyspepsia in general practice. BMJ. 1997 Nov 15;315(7118):1284–1288. doi: 10.1136/bmj.315.7118.1284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut. 1999 Apr;44 (Suppl 2):S1–16. doi: 10.1136/gut.44.2008.s1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol Suppl. 1996;215:38–47. [PubMed] [Google Scholar]
  7. Arvanitakis C., Nikopoułos A., Theoharidis A., Giannoulis E., Vagios I., Anthopoulou H., Michailidis D., Tourkantonis A. Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial. Aliment Pharmacol Ther. 1993 Dec;7(6):635–641. doi: 10.1111/j.1365-2036.1993.tb00145.x. [DOI] [PubMed] [Google Scholar]
  8. Atherton J. C. Non-endoscopic tests in the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Apr;11 (Suppl 1):11–20. doi: 10.1046/j.1365-2036.11.s1.3.x. [DOI] [PubMed] [Google Scholar]
  9. Axon A. T. Chronic dyspepsia: who needs endoscopy? Gastroenterology. 1997 Apr;112(4):1376–1380. doi: 10.1016/s0016-5085(97)70153-7. [DOI] [PubMed] [Google Scholar]
  10. Baldi F., Bianchi Porro G., Dobrilla G., Iascone C., Lobello R., Marzio L., Sabbatini F., Tittobello A., Verme G. Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial. J Clin Gastroenterol. 1988 Dec;10(6):614–618. doi: 10.1097/00004836-198812000-00007. [DOI] [PubMed] [Google Scholar]
  11. Bate C. M., Green J. R., Axon A. T., Murray F. E., Tildesley G., Emmas C. E., Taylor M. D. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther. 1997 Aug;11(4):755–763. doi: 10.1046/j.1365-2036.1997.00198.x. [DOI] [PubMed] [Google Scholar]
  12. Bate C. M., Griffin S. M., Keeling P. W., Axon A. T., Dronfield M. W., Chapman R. W., O'Donoghue D., Calam J., Crowe J., Mountfords R. A. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996 Aug;10(4):547–555. doi: 10.1046/j.1365-2036.1996.44186000.x. [DOI] [PubMed] [Google Scholar]
  13. Beck I. T., Champion M. C., Lemire S., Thomson A. B., Anvari M., Armstrong D., Bailey R. J., Barkun A. N., Boivin M., Bursey R. F. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can J Gastroenterol. 1997 Sep;11 (Suppl B):7B–20B. [PubMed] [Google Scholar]
  14. Bianchi Porro G., Petrillo M. The natural history of peptic ulcer disease: the influence of H2-antagonist treatment. Scand J Gastroenterol Suppl. 1986;121:46–52. doi: 10.3109/00365528609091678. [DOI] [PubMed] [Google Scholar]
  15. Blum A. L., Talley N. J., O'Moráin C., van Zanten S. V., Labenz J., Stolte M., Louw J. A., Stubberöd A., Theodórs A., Sundin M. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med. 1998 Dec 24;339(26):1875–1881. doi: 10.1056/NEJM199812243392602. [DOI] [PubMed] [Google Scholar]
  16. Bytzer P., Hansen J. M., Havelund T., Malchow-Møller A., Schaffalitzky de Muckadell O. B. Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement. Eur J Gastroenterol Hepatol. 1996 Apr;8(4):359–363. doi: 10.1097/00042737-199604000-00014. [DOI] [PubMed] [Google Scholar]
  17. Bytzer P., Hansen J. M., Schaffalitzky de Muckadell O. B. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet. 1994 Apr 2;343(8901):811–816. doi: 10.1016/s0140-6736(94)92023-0. [DOI] [PubMed] [Google Scholar]
  18. Carlsson R., Dent J., Bolling-Sternevald E., Johnsson F., Junghard O., Lauritsen K., Riley S., Lundell L. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol. 1998 Oct;33(10):1023–1029. doi: 10.1080/003655298750026697. [DOI] [PubMed] [Google Scholar]
  19. Carlsson R., Dent J., Watts R., Riley S., Sheikh R., Hatlebakk J., Haug K., de Groot G., van Oudvorst A., Dalväg A. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998 Feb;10(2):119–124. [PubMed] [Google Scholar]
  20. Carruthers S. G., Larochelle P., Haynes R. B., Petrasovits A., Schiffrin E. L. Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. CMAJ. 1993 Aug 1;149(3):289–293. [PMC free article] [PubMed] [Google Scholar]
  21. Chiba N., Bernard L., O'Brien B. J., Goeree R., Hunt R. H. A Canadian physician survey of dyspepsia management. Can J Gastroenterol. 1998 Jan-Feb;12(1):83–90. doi: 10.1155/1998/175926. [DOI] [PubMed] [Google Scholar]
  22. Chiba N., De Gara C. J., Wilkinson J. M., Hunt R. H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997 Jun;112(6):1798–1810. doi: 10.1053/gast.1997.v112.pm9178669. [DOI] [PubMed] [Google Scholar]
  23. Chiba N. Definitions of dyspepsia: time for a reappraisal. Eur J Surg Suppl. 1998;(583):14–23. doi: 10.1080/11024159850191184. [DOI] [PubMed] [Google Scholar]
  24. Chiba N., Lahaie R., Fedorak R. N., Bailey R., Veldhuyzen van Zanten S. J., Bernucci B. Helicobacter pylori and peptic ulcer disease. Current evidence for management strategies. Can Fam Physician. 1998 Jul;44:1481–1488. [PMC free article] [PubMed] [Google Scholar]
  25. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol. 1997 Sep;11 (Suppl B):66B–73B. [PubMed] [Google Scholar]
  26. Chiba N., Veldhuyzen Van Zanten S. J. 13C-Urea breath tests are the noninvasive method of choice for Helicobacter pylori detection. Can J Gastroenterol. 1999 Oct;13(8):681–683. [PubMed] [Google Scholar]
  27. Cullen D., Bardhan K. D., Eisner M., Kogut D. G., Peacock R. A., Thomson J. M., Hawkey C. J. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998 Feb;12(2):135–140. doi: 10.1046/j.1365-2036.1998.00288.x. [DOI] [PubMed] [Google Scholar]
  28. Dakkak M., Jones B. P., Scott M. G., Tooley P. J., Bennett J. R. Comparing the efficacy of cisapride and ranitidine in oesophagitis: a double-blind, parallel group study in general practice. Br J Clin Pract. 1994 Jan-Feb;48(1):10–14. [PubMed] [Google Scholar]
  29. DeVault K. R., Castell D. O. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med. 1995 Nov 13;155(20):2165–2173. [PubMed] [Google Scholar]
  30. Dent J. Gastro-oesophageal reflux disease. Digestion. 1998 Aug;59(5):433–445. doi: 10.1159/000007521. [DOI] [PubMed] [Google Scholar]
  31. Dettmer A., Vogt R., Sielaff F., Lühmann R., Schneider A., Fischer R. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment Pharmacol Ther. 1998 Sep;12(9):865–872. doi: 10.1046/j.1365-2036.1998.00381.x. [DOI] [PubMed] [Google Scholar]
  32. Dimenäs E., Glise H., Hallerbäck B., Hernqvist H., Svedlund J., Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol. 1993 Aug;28(8):681–687. doi: 10.3109/00365529309098272. [DOI] [PubMed] [Google Scholar]
  33. Dooley C. P., Larson A. W., Stace N. H., Renner I. G., Valenzuela J. E., Eliasoph J., Colletti P. M., Halls J. M., Weiner J. M. Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study. Ann Intern Med. 1984 Oct;101(4):538–545. doi: 10.7326/0003-4819-101-4-538. [DOI] [PubMed] [Google Scholar]
  34. Ehsanullah R. S., Page M. C., Tildesley G., Wood J. R. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 1988 Oct 22;297(6655):1017–1021. doi: 10.1136/bmj.297.6655.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ekström P., Carling L., Wetterhus S., Wingren P. E., Anker-Hansen O., Lundegårdh G., Thorhallsson E., Unge P. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol. 1996 Aug;31(8):753–758. doi: 10.3109/00365529609010347. [DOI] [PubMed] [Google Scholar]
  36. Elliott S. L., Yeomans N. D., Buchanan R. R., Smallwood R. A. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial. Scand J Rheumatol. 1994;23(4):171–176. doi: 10.3109/03009749409103056. [DOI] [PubMed] [Google Scholar]
  37. Emery P., Zeidler H., Kvien T. K., Guslandi M., Naudin R., Stead H., Verburg K. M., Isakson P. C., Hubbard R. C., Geis G. S. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999 Dec 18;354(9196):2106–2111. doi: 10.1016/S0140-6736(99)02332-6. [DOI] [PubMed] [Google Scholar]
  38. Fallone C. A., Loo V. G., Barkun A. N. Utility of serology in determining Helicobacter pylori eradication after therapy. Can J Gastroenterol. 1998 Mar;12(2):117–124. doi: 10.1155/1998/303628. [DOI] [PubMed] [Google Scholar]
  39. Fallone C. A., Mitchell A., Paterson W. G. Determination of the test performance of less costly methods of Helicobacter pylori detection. Clin Invest Med. 1995 Jun;18(3):177–185. [PubMed] [Google Scholar]
  40. Feldman M., McMahon A. T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med. 2000 Jan 18;132(2):134–143. doi: 10.7326/0003-4819-132-2-200001180-00008. [DOI] [PubMed] [Google Scholar]
  41. Fraser A. G., Ali M. R., McCullough S., Yeates N. J., Haystead A. Diagnostic tests for Helicobacter pylori--can they help select patients for endoscopy? N Z Med J. 1996 Mar 22;109(1018):95–98. [PubMed] [Google Scholar]
  42. Fraser A. G., McIntosh C., Berry S., Moore L. Can the urea breath test for H.pylori replace endoscopy for the assessment of dyspepsia in primary care? N Z Med J. 1998 Jan 23;111(1058):11–14. [PubMed] [Google Scholar]
  43. Funch-Jensen P. Is this a reflux patient or is it a patient with functional dyspepsia with additional reflux symptoms? Scand J Gastroenterol Suppl. 1995;211:29–31. doi: 10.3109/00365529509090290. [DOI] [PubMed] [Google Scholar]
  44. Gabriel S. E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991 Nov 15;115(10):787–796. doi: 10.7326/0003-4819-115-10-787. [DOI] [PubMed] [Google Scholar]
  45. Galmiche J. P., Barthelemy P., Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997 Aug;11(4):765–773. doi: 10.1046/j.1365-2036.1997.00185.x. [DOI] [PubMed] [Google Scholar]
  46. Galmiche J. P., Brandstätter G., Evreux M., Hentschel E., Kerstan E., Kratochvil P., Reichel W., Schütze K., Soule J. C., Vitaux J. Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial. Gut. 1988 May;29(5):675–681. doi: 10.1136/gut.29.5.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Galmiche J. P., Fraitag B., Filoche B., Evreux M., Vitaux J., Zeitoun P., Fournet J., Soule J. C. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci. 1990 May;35(5):649–655. doi: 10.1007/BF01540415. [DOI] [PubMed] [Google Scholar]
  48. García Rodríguez L. A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994 Mar 26;343(8900):769–772. doi: 10.1016/s0140-6736(94)91843-0. [DOI] [PubMed] [Google Scholar]
  49. Geldof H., Hazelhoff B., Otten M. H. Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther. 1993 Aug;7(4):409–415. doi: 10.1111/j.1365-2036.1993.tb00114.x. [DOI] [PubMed] [Google Scholar]
  50. Gillen D., McColl K. E. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol. 1999 Jan;94(1):75–79. doi: 10.1111/j.1572-0241.1999.00774.x. [DOI] [PubMed] [Google Scholar]
  51. Gilvarry J., Buckley M. J., Beattie S., Hamilton H., O'Morain C. A. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol. 1997 Jun;32(6):535–540. doi: 10.3109/00365529709025095. [DOI] [PubMed] [Google Scholar]
  52. Gotthard R., Bodemar G., Brodin U., Jönsson K. A. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol. 1988 Jan;23(1):7–18. doi: 10.3109/00365528809093840. [DOI] [PubMed] [Google Scholar]
  53. Goves J., Oldring J. K., Kerr D., Dallara R. G., Roffe E. J., Powell J. A., Taylor M. D. First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther. 1998 Feb;12(2):147–157. doi: 10.1046/j.1365-2036.1998.0284f.x. [DOI] [PubMed] [Google Scholar]
  54. Graham D. Y., Patterson D. J. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983 Jun;28(6):559–563. doi: 10.1007/BF01308159. [DOI] [PubMed] [Google Scholar]
  55. Graham D. Y. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med. 1993 Feb 4;328(5):349–350. doi: 10.1056/NEJM199302043280512. [DOI] [PubMed] [Google Scholar]
  56. Graham D. Y., White R. H., Moreland L. W., Schubert T. T., Katz R., Jaszewski R., Tindall E., Triadafilopoulos G., Stromatt S. C., Teoh L. S. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med. 1993 Aug 15;119(4):257–262. doi: 10.7326/0003-4819-119-4-199308150-00001. [DOI] [PubMed] [Google Scholar]
  57. Grainger S. L., Klass H. J., Rake M. O., Williams J. G. Prevalence of dyspepsia: the epidemiology of overlapping symptoms. Postgrad Med J. 1994 Mar;70(821):154–161. doi: 10.1136/pgmj.70.821.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Greenlaw R., Sheahan D. G., DeLuca V., Miller D., Myerson D., Myerson P. Gastroduodenitis. A broader concept of peptic ulcer disease. Dig Dis Sci. 1980 Sep;25(9):660–672. doi: 10.1007/BF01308325. [DOI] [PubMed] [Google Scholar]
  59. Grove O., Bekker C., Jeppe-Hansen M. G., Karstoft E., Sanchez G., Axelsson C. K., Nielsen H. O., Andersen B., Rask-Madsen J. Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial. Scand J Gastroenterol. 1985 May;20(4):457–461. doi: 10.3109/00365528509089680. [DOI] [PubMed] [Google Scholar]
  60. Hallas J., Bytzer P. Screening for drug related dyspepsia: an analysis of prescription symmetry. Eur J Gastroenterol Hepatol. 1998 Jan;10(1):27–32. doi: 10.1097/00042737-199801000-00006. [DOI] [PubMed] [Google Scholar]
  61. Hallissey M. T., Allum W. H., Jewkes A. J., Ellis D. J., Fielding J. W. Early detection of gastric cancer. BMJ. 1990 Sep 15;301(6751):513–515. doi: 10.1136/bmj.301.6751.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Hamilton J. W., Boisen R. J., Yamamoto D. T., Wagner J. L., Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988 May;33(5):518–522. doi: 10.1007/BF01798350. [DOI] [PubMed] [Google Scholar]
  63. Hamlet A. K., Erlandsson K. I., Olbe L., Svennerholm A. M., Backman V. E., Pettersson A. B. A simple, rapid, and highly reliable capsule-based 14C urea breath test for diagnosis of Helicobacter pylori infection. Scand J Gastroenterol. 1995 Nov;30(11):1058–1063. doi: 10.3109/00365529509101607. [DOI] [PubMed] [Google Scholar]
  64. Hansen J. M., Bytzer P., Bondesen S., Schaffalitzky de Muckadell O. B. Efficacy and outcome of an open access endoscopy service. Dan Med Bull. 1991 Jun;38(3):288–290. [PubMed] [Google Scholar]
  65. Harvey R. F., Gordon P. C., Hadley N., Long D. E., Gill T. R., Macpherson R. I., Beats B. C., Tottle A. J. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet. 1987 Nov 21;2(8569):1200–1203. doi: 10.1016/s0140-6736(87)91332-8. [DOI] [PubMed] [Google Scholar]
  66. Hatlebakk J. G., Hyggen A., Madsen P. H., Walle P. O., Schulz T., Mowinckel P., Bernklev T., Berstad A. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ. 1999 Aug 28;319(7209):550–553. doi: 10.1136/bmj.319.7209.550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Hawkey C. J. COX-2 inhibitors. Lancet. 1999 Jan 23;353(9149):307–314. doi: 10.1016/s0140-6736(98)12154-2. [DOI] [PubMed] [Google Scholar]
  68. Hawkey C. J., Karrasch J. A., Szczepañski L., Walker D. G., Barkun A., Swannell A. J., Yeomans N. D. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998 Mar 12;338(11):727–734. doi: 10.1056/NEJM199803123381105. [DOI] [PubMed] [Google Scholar]
  69. Hawkey C. J. What do we do about Helicobacter pylori? Can J Gastroenterol. 1999 Mar;13(2):143–145. doi: 10.1155/1999/307387. [DOI] [PubMed] [Google Scholar]
  70. Heading R. C. Definitions of dyspepsia. Scand J Gastroenterol Suppl. 1991;182:1–6. doi: 10.3109/00365529109109529. [DOI] [PubMed] [Google Scholar]
  71. Heaney A., Collins J. S., Watson R. G., McFarland R. J., Bamford K. B., Tham T. C. A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut. 1999 Aug;45(2):186–190. doi: 10.1136/gut.45.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Heikkinen M., Pikkarainen P., Takala J., Räsänen H., Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol. 1995 Jun;30(6):519–523. doi: 10.3109/00365529509089783. [DOI] [PubMed] [Google Scholar]
  73. Howden C. W. For what conditions is there evidence-based justification for treatment of Helicobacter pylori infection? Gastroenterology. 1997 Dec;113(6 Suppl):S107–S112. doi: 10.1016/s0016-5085(97)80022-4. [DOI] [PubMed] [Google Scholar]
  74. Hudson N., Taha A. S., Russell R. I., Trye P., Cottrell J., Mann S. G., Swanell A. J., Sturrock R. D., Hawkey C. J. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 1997 Jun;112(6):1817–1822. doi: 10.1053/gast.1997.v112.pm9178671. [DOI] [PubMed] [Google Scholar]
  75. Hunt R. H., Fallone C. A., Thomson A. B. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol. 1999 Apr;13(3):213–217. doi: 10.1155/1999/180751. [DOI] [PubMed] [Google Scholar]
  76. Hunt R. H. The role of Helicobacter pylori in pathogenesis: the spectrum of clinical outcomes. Scand J Gastroenterol Suppl. 1996;220:3–9. [PubMed] [Google Scholar]
  77. Hunt R., Thomson A. B. Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Can J Gastroenterol. 1998 Jan-Feb;12(1):31–41. doi: 10.1155/1998/170180. [DOI] [PubMed] [Google Scholar]
  78. Hunt R., Thomson A. B. Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Can J Gastroenterol. 1998 Jan-Feb;12(1):31–41. doi: 10.1155/1998/170180. [DOI] [PubMed] [Google Scholar]
  79. Inoue M., Sekiguchi T., Harasawa S., Miwa T., Miyoshi A. Dyspepsia and dyspepsia subgroups in Japan: symptom profiles and experience with cisapride. Scand J Gastroenterol Suppl. 1993;195:36–39. doi: 10.3109/00365529309098326. [DOI] [PubMed] [Google Scholar]
  80. Jaakkimainen R. L., Boyle E., Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ. 1999 Oct 16;319(7216):1040–1044. doi: 10.1136/bmj.319.7216.1040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Janisch H. D., Hüttemann W., Bouzo M. H. Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepatogastroenterology. 1988 Jun;35(3):125–127. [PubMed] [Google Scholar]
  82. Johannessen T., Petersen H., Kleveland P. M., Dybdahl J. H., Sandvik A. K., Brenna E., Waldum H. The predictive value of history in dyspepsia. Scand J Gastroenterol. 1990 Jul;25(7):689–697. doi: 10.3109/00365529008997594. [DOI] [PubMed] [Google Scholar]
  83. Johannessen T., Petersen H., Kristensen P., Kleveland P. M., Dybdahl J., Sandvik A. K., Brenna E., Waldum H. The intensity and variability of symptoms in dyspepsia. Scand J Prim Health Care. 1993 Mar;11(1):50–55. doi: 10.3109/02813439308994902. [DOI] [PubMed] [Google Scholar]
  84. Johnson L. F., DeMeester T. R. Evaluation of elevation of the head of the bed, bethanechol, and antacid form tablets on gastroesophageal reflux. Dig Dis Sci. 1981 Aug;26(8):673–680. doi: 10.1007/BF01316854. [DOI] [PubMed] [Google Scholar]
  85. Jones R. H., Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther. 1997 Jun;11(3):541–546. doi: 10.1046/j.1365-2036.1997.00179.x. [DOI] [PubMed] [Google Scholar]
  86. Jones R. H., Lydeard S. E., Hobbs F. D., Kenkre J. E., Williams E. I., Jones S. J., Repper J. A., Caldow J. L., Dunwoodie W. M., Bottomley J. M. Dyspepsia in England and Scotland. Gut. 1990 Apr;31(4):401–405. doi: 10.1136/gut.31.4.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Jones R., Lydeard S. Dyspepsia in the community: a follow-up study. Br J Clin Pract. 1992 Summer;46(2):95–97. [PubMed] [Google Scholar]
  88. Kay L., Jørgensen T. Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors. Scand J Gastroenterol. 1994 Jan;29(1):2–6. [PubMed] [Google Scholar]
  89. Kiil J., Andersen D. X-ray examination and/or endoscopy in the diagnosis of gastroduodenal ulcer and cancer. Scand J Gastroenterol. 1980;15(1):39–43. doi: 10.3109/00365528009181429. [DOI] [PubMed] [Google Scholar]
  90. Kimmig J. M. Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies. Aliment Pharmacol Ther. 1995 Jun;9(3):281–286. doi: 10.1111/j.1365-2036.1995.tb00382.x. [DOI] [PubMed] [Google Scholar]
  91. Kitchin L. I., Castell D. O. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med. 1991 Mar;151(3):448–454. [PubMed] [Google Scholar]
  92. Kjellin A., Ramel S., Rössner S., Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol. 1996 Nov;31(11):1047–1051. doi: 10.3109/00365529609036885. [DOI] [PubMed] [Google Scholar]
  93. Klauser A. G., Schindlbeck N. E., Müller-Lissner S. A. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990 Jan 27;335(8683):205–208. doi: 10.1016/0140-6736(90)90287-f. [DOI] [PubMed] [Google Scholar]
  94. Klauser A. G., Voderholzer W. A., Knesewitsch P. A., Schindlbeck N. E., Müller-Lissner S. A. What is behind dyspepsia? Dig Dis Sci. 1993 Jan;38(1):147–154. doi: 10.1007/BF01296788. [DOI] [PubMed] [Google Scholar]
  95. Knill-Jones R. P. Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol Suppl. 1991;182:17–24. doi: 10.3109/00365529109109532. [DOI] [PubMed] [Google Scholar]
  96. Koelz H. R. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials. Scand J Gastroenterol Suppl. 1989;156:25–36. [PubMed] [Google Scholar]
  97. Laheij R. J., Severens J. L., Van de Lisdonk E. H., Verbeek A. L., Jansen J. B. Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis. Aliment Pharmacol Ther. 1998 Dec;12(12):1249–1256. doi: 10.1046/j.1365-2036.1998.00423.x. [DOI] [PubMed] [Google Scholar]
  98. Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H., Stern S., Quan H., Bolognese J. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology. 1999 Oct;117(4):776–783. doi: 10.1016/s0016-5085(99)70334-3. [DOI] [PubMed] [Google Scholar]
  99. Langman M. J., Jensen D. M., Watson D. J., Harper S. E., Zhao P. L., Quan H., Bolognese J. A., Simon T. J. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999 Nov 24;282(20):1929–1933. doi: 10.1001/jama.282.20.1929. [DOI] [PubMed] [Google Scholar]
  100. Lanza F. L., Rack M. F., Simon T. J., Quan H., Bolognese J. A., Hoover M. E., Wilson F. R., Harper S. E. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther. 1999 Jun;13(6):761–767. doi: 10.1046/j.1365-2036.1999.00529.x. [DOI] [PubMed] [Google Scholar]
  101. Lemire S. Assessment of clinical severity and investigation of uncomplicated gastroesophageal reflux disease and noncardiac angina-like chest pain. Can J Gastroenterol. 1997 Sep;11 (Suppl B):37B–40B. [PubMed] [Google Scholar]
  102. Lepoutre L., Van der Spek P., Vanderlinden I., Bollen J., Laukens P. Healing of grade-II and III oesophagitis through motility stimulation with cisapride. Digestion. 1990;45(2):109–114. doi: 10.1159/000200231. [DOI] [PubMed] [Google Scholar]
  103. Levine L. R., Cloud M. L., Enas N. H. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1993 Nov 8;153(21):2449–2454. [PubMed] [Google Scholar]
  104. Lind T., Havelund T., Carlsson R., Anker-Hansen O., Glise H., Hernqvist H., Junghard O., Lauritsen K., Lundell L., Pedersen S. A. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997 Oct;32(10):974–979. doi: 10.3109/00365529709011212. [DOI] [PubMed] [Google Scholar]
  105. Loy C. T., Irwig L. M., Katelaris P. H., Talley N. J. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol. 1996 Jun;91(6):1138–1144. [PubMed] [Google Scholar]
  106. Lydeard S., Jones R. Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract. 1989 Dec;39(329):495–498. [PMC free article] [PubMed] [Google Scholar]
  107. MacDonald T. M., Morant S. V., Robinson G. C., Shield M. J., McGilchrist M. M., Murray F. E., McDevitt D. G. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ. 1997 Nov 22;315(7119):1333–1337. doi: 10.1136/bmj.315.7119.1333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Malaty H. M., Graham D. Y. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut. 1994 Jun;35(6):742–745. doi: 10.1136/gut.35.6.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Maleev A., Mendizova A., Popov P., Vlahov V., Dimitrov B., Mihova A., Crowe J., Silveira J., Thomson A., Routhier G. Cisapride and cimetidine in the treatment of erosive esophagitis. Hepatogastroenterology. 1990 Aug;37(4):403–407. [PubMed] [Google Scholar]
  110. Management of dyspepsia: report of a working party. Lancet. 1988 Mar 12;1(8585):576–579. [PubMed] [Google Scholar]
  111. Mansfield J. C., Greenaway J. R., Contractor B. R., Idle N., Bramble M. G. Open access gastroscopy findings are unrelated to the use of aspirin and non-steroidal anti-inflammatory drugs. Br J Gen Pract. 1997 Dec;47(425):825–826. [PMC free article] [PubMed] [Google Scholar]
  112. Marshall J. K., Armstrong D., O'Brien B. J. Test and treat strategies for Helicobacter pylori in uninvestigated dyspepsia: a Canadian economic analysis. Can J Gastroenterol. 2000 May;14(5):379–388. doi: 10.1155/2000/978035. [DOI] [PubMed] [Google Scholar]
  113. Martin T. R., Vennes J. A., Silvis S. E., Ansel H. J. A comparison of upper gastrointestinal endoscopy and radiography. J Clin Gastroenterol. 1980 Mar;2(1):21–25. doi: 10.1097/00004836-198003000-00004. [DOI] [PubMed] [Google Scholar]
  114. Mason I., Millar L. J., Sheikh R. R., Evans W. M., Todd P. L., Turbitt M. L., Taylor M. D. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. Aliment Pharmacol Ther. 1998 Mar;12(3):263–271. doi: 10.1046/j.1365-2036.1998.00282.x. [DOI] [PubMed] [Google Scholar]
  115. McCarthy D. M. Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):662–674. doi: 10.1016/s0016-5085(89)80063-0. [DOI] [PubMed] [Google Scholar]
  116. McColl K., Murray L., El-Omar E., Dickson A., El-Nujumi A., Wirz A., Kelman A., Penny C., Knill-Jones R., Hilditch T. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998 Dec 24;339(26):1869–1874. doi: 10.1056/NEJM199812243392601. [DOI] [PubMed] [Google Scholar]
  117. McKenna C. J., Mills J. G., Goodwin C., Wood J. R. Combination of ranitidine and cisapride in the treatment of reflux oesophagitis. Eur J Gastroenterol Hepatol. 1995 Sep;7(9):817–822. [PubMed] [Google Scholar]
  118. Mizuno H., Sakamoto C., Matsuda K., Wada K., Uchida T., Noguchi H., Akamatsu T., Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997 Feb;112(2):387–397. doi: 10.1053/gast.1997.v112.pm9024292. [DOI] [PubMed] [Google Scholar]
  119. Moayyedi P., Carter A. M., Catto A., Heppell R. M., Grant P. J., Axon A. T. Validation of a rapid whole blood test for diagnosing Helicobacter pylori infection. BMJ. 1997 Jan 11;314(7074):119–119. doi: 10.1136/bmj.314.7074.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Moayyedi P. Do young dyspeptics require endoscopy any more? Eur J Gastroenterol Hepatol. 1999 Aug;11 (Suppl 2):S59–S73. doi: 10.1097/00042737-199908002-00012. [DOI] [PubMed] [Google Scholar]
  121. Mowat C., Murray L., Hilditch T. E., Kelman A., Oien K., McColl K. E. Comparison of helisal rapid blood test and 14C-urea breath test in determining Helicobacter pylori status and predicting ulcer disease in dyspeptic patients. Am J Gastroenterol. 1998 Jan;93(1):20–25. doi: 10.1111/j.1572-0241.1998.020_c.x. [DOI] [PubMed] [Google Scholar]
  122. Nandurkar S., Talley N. J., Xia H., Mitchell H., Hazel S., Jones M. Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Arch Intern Med. 1998 Jul 13;158(13):1427–1433. doi: 10.1001/archinte.158.13.1427. [DOI] [PubMed] [Google Scholar]
  123. Nyrén O., Adami H. O., Bates S., Bergström R., Gustavsson S., Löf L., Nyberg A. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med. 1986 Feb 6;314(6):339–343. doi: 10.1056/NEJM198602063140603. [DOI] [PubMed] [Google Scholar]
  124. Nørrelund N., Helles A., Schmiegelow M. Ukarakteristisk dyspepsi i almen praksis. En kontrolleret undersøgelse med et antacidum (Alminox). Ugeskr Laeger. 1980 Jun 30;142(27):1750–1753. [PubMed] [Google Scholar]
  125. Ott D. J., McManus C. M., Ledbetter M. S., Chen M. Y., Gelfand D. W. Heartburn correlated to 24-hour pH monitoring and radiographic examination of the esophagus. Am J Gastroenterol. 1997 Oct;92(10):1827–1830. [PubMed] [Google Scholar]
  126. Parsonnet J., Harris R. A., Hack H. M., Owens D. K. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996 Jul 20;348(9021):150–154. doi: 10.1016/s0140-6736(96)01501-2. [DOI] [PubMed] [Google Scholar]
  127. Patel P., Khulusi S., Mendall M. A., Lloyd R., Jazrawi R., Maxwell J. D., Northfield T. C. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet. 1995 Nov 18;346(8986):1315–1318. doi: 10.1016/s0140-6736(95)92340-3. [DOI] [PubMed] [Google Scholar]
  128. Penston J. G., Pounder R. E. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther. 1996 Feb;10(1):83–89. doi: 10.1111/j.1365-2036.1996.tb00180.x. [DOI] [PubMed] [Google Scholar]
  129. Raskin J. B., White R. H., Jaszewski R., Korsten M. A., Schubert T. T., Fort J. G. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996 Feb;91(2):223–227. [PubMed] [Google Scholar]
  130. Reynolds J. C. Individualized acute treatment strategies for gastroesophageal reflux disease. Scand J Gastroenterol Suppl. 1995;213:17–24. [PubMed] [Google Scholar]
  131. Richter J. E., Long J. F. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. Am J Gastroenterol. 1995 Mar;90(3):423–430. [PubMed] [Google Scholar]
  132. Robertson C. S., Evans D. F., Ledingham S. J., Atkinson M. Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993 Apr;7(2):181–190. doi: 10.1111/j.1365-2036.1993.tb00088.x. [DOI] [PubMed] [Google Scholar]
  133. Robinson M., Mills R. J., Euler A. R. Ranitidine prevents duodenal ulcers associated with non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther. 1991 Apr;5(2):143–150. doi: 10.1111/j.1365-2036.1991.tb00015.x. [DOI] [PubMed] [Google Scholar]
  134. Sandha G. S., Hunt R. H., Veldhuyzen van Zanten S. J. A systematic overview of the use of diary cards, quality-of-life questionnaires, and psychometric tests in treatment trials of Helicobacter pylori-positive and -negative non-ulcer dyspepsia. Scand J Gastroenterol. 1999 Mar;34(3):244–249. doi: 10.1080/00365529950173636. [DOI] [PubMed] [Google Scholar]
  135. Schmassmann A., Peskar B. M., Stettler C., Netzer P., Stroff T., Flogerzi B., Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol. 1998 Mar;123(5):795–804. doi: 10.1038/sj.bjp.0701672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Shaw P. C., van Romunde L. K., Griffioen G., Janssens A. R., Kreuning J., Eilers G. A. Peptic ulcer and gastric carcinoma: diagnosis with biphasic radiography compared with fiberoptic endoscopy. Radiology. 1987 Apr;163(1):39–42. doi: 10.1148/radiology.163.1.3823455. [DOI] [PubMed] [Google Scholar]
  137. Silverstein M. D., Petterson T., Talley N. J. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology. 1996 Jan;110(1):72–83. doi: 10.1053/gast.1996.v110.pm8536890. [DOI] [PubMed] [Google Scholar]
  138. Simon L. S., Weaver A. L., Graham D. Y., Kivitz A. J., Lipsky P. E., Hubbard R. C., Isakson P. C., Verburg K. M., Yu S. S., Zhao W. W. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999 Nov 24;282(20):1921–1928. doi: 10.1001/jama.282.20.1921. [DOI] [PubMed] [Google Scholar]
  139. Small P. K., Loudon M. A., Waldron B., Smith D., Campbell F. C. Importance of reflux symptoms in functional dyspepsia. Gut. 1995 Feb;36(2):189–192. doi: 10.1136/gut.36.2.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Sue-Ling H. M., Johnston D., Martin I. G., Dixon M. F., Lansdown M. R., McMahon M. J., Axon A. T. Gastric cancer: a curable disease in Britain. BMJ. 1993 Sep 4;307(6904):591–596. doi: 10.1136/bmj.307.6904.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Taha A. S., Dahill S., Sturrock R. D., Lee F. D., Russell R. I. Predicting NSAID related ulcers--assessment of clinical and pathological risk factors and importance of differences in NSAID. Gut. 1994 Jul;35(7):891–895. doi: 10.1136/gut.35.7.891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Taha A. S., Hudson N., Hawkey C. J., Swannell A. J., Trye P. N., Cottrell J., Mann S. G., Simon T. J., Sturrock R. D., Russell R. I. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996 May 30;334(22):1435–1439. doi: 10.1056/NEJM199605303342204. [DOI] [PubMed] [Google Scholar]
  143. Talley N. J., Hunt R. H. What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology. 1997 Dec;113(6 Suppl):S67–S77. doi: 10.1016/s0016-5085(97)80016-9. [DOI] [PubMed] [Google Scholar]
  144. Talley N. J., Janssens J., Lauritsen K., Rácz I., Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ. 1999 Mar 27;318(7187):833–837. doi: 10.1136/bmj.318.7187.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Talley N. J., McNeil D., Hayden A., Colreavy C., Piper D. W. Prognosis of chronic unexplained dyspepsia. A prospective study of potential predictor variables in patients with endoscopically diagnosed nonulcer dyspepsia. Gastroenterology. 1987 Apr;92(4):1060–1066. [PubMed] [Google Scholar]
  146. Talley N. J., Meineche-Schmidt V., Paré P., Duckworth M., Räisänen P., Pap A., Kordecki H., Schmid V. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998 Nov;12(11):1055–1065. doi: 10.1046/j.1365-2036.1998.00410.x. [DOI] [PubMed] [Google Scholar]
  147. Talley N. J., Vakil N., Ballard E. D., 2nd, Fennerty M. B. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 1999 Oct 7;341(15):1106–1111. doi: 10.1056/NEJM199910073411502. [DOI] [PubMed] [Google Scholar]
  148. Talley N. J., Weaver A. L., Tesmer D. L., Zinsmeister A. R. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology. 1993 Nov;105(5):1378–1386. doi: 10.1016/0016-5085(93)90142-y. [DOI] [PubMed] [Google Scholar]
  149. Talley N. J., Weaver A. L., Zinsmeister A. R., Melton L. J., 3rd Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol. 1992 Jul 15;136(2):165–177. doi: 10.1093/oxfordjournals.aje.a116483. [DOI] [PubMed] [Google Scholar]
  150. Talley N. J., Weaver A. L., Zinsmeister A. R. Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups. Am J Gastroenterol. 1994 Apr;89(4):524–528. [PubMed] [Google Scholar]
  151. Talley N. J., Zinsmeister A. R., Schleck C. D., Melton L. J., 3rd Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992 Apr;102(4 Pt 1):1259–1268. [PubMed] [Google Scholar]
  152. Talley N. J., Zinsmeister A. R., Schleck C. D., Melton L. J., 3rd Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups: lack of an association in a community. Gut. 1994 May;35(5):619–624. doi: 10.1136/gut.35.5.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Thijs J. C., van Zwet A. A., Thijs W. J., Oey H. B., Karrenbeld A., Stellaard F., Luijt D. S., Meyer B. C., Kleibeuker J. H. Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol. 1996 Oct;91(10):2125–2129. [PubMed] [Google Scholar]
  154. Tougas G., Chen Y., Hwang P., Liu M. M., Eggleston A. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. Am J Gastroenterol. 1999 Oct;94(10):2845–2854. doi: 10.1111/j.1572-0241.1999.01427.x. [DOI] [PubMed] [Google Scholar]
  155. Uemura N., Mukai T., Okamoto S., Yamaguchi S., Mashiba H., Taniyama K., Sasaki N., Haruma K., Sumii K., Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):639–642. [PubMed] [Google Scholar]
  156. Veldhuyzen van Zanten S. J. Can the age limit for endoscopy be increased in dyspepsia patients who do not have alarm symptoms? Am J Gastroenterol. 1999 Jan;94(1):9–11. doi: 10.1016/s0002-9270(98)00640-6. [DOI] [PubMed] [Google Scholar]
  157. Veldhuyzen van Zanten S. J., Cleary C., Talley N. J., Peterson T. C., Nyrén O., Bradley L. A., Verlinden M., Tytgat G. N. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol. 1996 Apr;91(4):660–673. [PubMed] [Google Scholar]
  158. Veldhuyzen van Zanten S. J. Do socio-economic status, marital status and occupation influence the prevalence of Helicobacter pylori infection? Aliment Pharmacol Ther. 1995;9 (Suppl 2):41–44. [PubMed] [Google Scholar]
  159. Veldhuyzen van Zanten S. J., Pollak P. T., Best L. M., Bezanson G. S., Marrie T. Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis. 1994 Feb;169(2):434–437. doi: 10.1093/infdis/169.2.434. [DOI] [PubMed] [Google Scholar]
  160. Veldhuyzen van Zanten S. J., Sherman P. M. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. CMAJ. 1994 Jan 15;150(2):177–185. [PMC free article] [PubMed] [Google Scholar]
  161. Veldhuyzen van Zanten S. J., Sherman P. M., Hunt R. H. Helicobacter pylori: new developments and treatments. CMAJ. 1997 Jun 1;156(11):1565–1574. [PMC free article] [PubMed] [Google Scholar]
  162. Veldhuyzen van Zanten S. J., Tytgat K. M., Hollingsworth J., Jalali S., Rshid F. A., Bowen B. M., Goldie J., Goodacre R. L., Riddell R. H., Hunt R. H. 14C-urea breath test for the detection of Helicobacter pylori. Am J Gastroenterol. 1990 Apr;85(4):399–403. [PubMed] [Google Scholar]
  163. Venables T. L., Newland R. D., Patel A. C., Hole J., Wilcock C., Turbitt M. L. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997 Oct;32(10):965–973. doi: 10.3109/00365529709011211. [DOI] [PubMed] [Google Scholar]
  164. Weberg R., Berstad A. Low-dose antacids and pirenzepine in the treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A randomized, double-blind, placebo-controlled trial. Scand J Gastroenterol. 1988 Mar;23(2):237–243. doi: 10.3109/00365528809103974. [DOI] [PubMed] [Google Scholar]
  165. Weberg R., Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol. 1989 May;24(4):401–406. doi: 10.3109/00365528909093066. [DOI] [PubMed] [Google Scholar]
  166. Weir R. D., Backett E. M. Studies of the epidemiology of peptic ulcer in a rural community: prevalence and natural history of dyspepsia and peptic ulcer. Gut. 1968 Feb;9(1):75–83. doi: 10.1136/gut.9.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Whitaker M. J., Brun J., Carelli F. Controversy and consensus in the management of upper gastrointestinal disease in primary care. The International Gastro Primary Care Group. Int J Clin Pract. 1997 Jun;51(4):239–243. [PubMed] [Google Scholar]
  168. Wiklund I., Glise H., Jerndal P., Carlsson J., Talley N. J. Does endoscopy have a positive impact on quality of life in dyspepsia? Gastrointest Endosc. 1998 Jun;47(6):449–454. doi: 10.1016/s0016-5107(98)70243-3. [DOI] [PubMed] [Google Scholar]
  169. Williams B., Luckas M., Ellingham J. H., Dain A., Wicks A. C. Do young patients with dyspepsia need investigation? Lancet. 1988 Dec 10;2(8624):1349–1351. doi: 10.1016/s0140-6736(88)90879-3. [DOI] [PubMed] [Google Scholar]
  170. Wysowski D. K., Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996 Jul 25;335(4):290–291. doi: 10.1056/NEJM199607253350416. [DOI] [PubMed] [Google Scholar]
  171. Yeomans N. D., Tulassay Z., Juhász L., Rácz I., Howard J. M., van Rensburg C. J., Swannell A. J., Hawkey C. J. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998 Mar 12;338(11):719–726. doi: 10.1056/NEJM199803123381104. [DOI] [PubMed] [Google Scholar]
  172. ten Wolde S., Dijkmans B. A., Janssen M., Hermans J., Lamers C. B. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Aliment Pharmacol Ther. 1996 Jun;10(3):347–351. doi: 10.1111/j.0953-0673.1996.00347.x. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES